Avidity Biosciences (RNA) Stock Forecast & Price Target

$13.07 +0.11 (+0.85%)

As of 04:00 PM Eastern

Compare

Avidity Biosciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 19 Analyst Ratings

Sell
1

Hold
12

Buy
6

Based on 19 Wall Street analysts who have issued ratings for Avidity Biosciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 19 analysts, 1 has given a sell rating, 12 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for RNA.

Consensus Price Target

$69.42
431.15% Upside

According to the 19 analysts' twelve-month price targets for Avidity Biosciences, the average price target is $69.42. The highest price target for RNA is $96.00, while the lowest price target for RNA is $55.00. The average price target represents a forecasted upside of 431.15% from the current price of $13.07.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for RNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Avidity Biosciences and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RNA Analyst Ratings Over Time

Type	Current Forecast 5/8/25 to 5/8/26	1 Month Ago 4/8/25 to 4/8/26	3 Months Ago 2/7/25 to 2/7/26	1 Year Ago 5/8/24 to 5/8/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	8 Buy rating(s)	13 Buy rating(s)
Hold	12 Hold rating(s)	12 Hold rating(s)	12 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$69.42	$69.42	$69.57	$66.69
Forecasted Upside	431.15% Upside	406.72% Upside	-4.57% Downside	131.83% Upside
Consensus Rating	Hold	Hold	Hold	Buy

RNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Avidity Biosciences Stock vs. The Competition

Type	Avidity Biosciences	Medical Companies	S&P 500
Consensus Rating Score	2.32	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	426.72% Upside	847.95% Upside	15.60% Upside
News Sentiment Rating	Neutral News See Recent RNA News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/1/2026	HC Wainwright 3 of 5 stars	Ananda Ghosh Not Rated	Reiterated Rating	Neutral
3/11/2026	Wells Fargo & Company 3 of 5 stars	Yanan Zhu 2 of 5 stars	Initiated Coverage	Overweight
1/21/2026	Weiss Ratings Not Rated		Reiterated Rating	Sell (D-)
12/18/2025	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Josh Schimmer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$72.00	-0.16%
11/12/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
11/11/2025	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Keay Nakae Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$72.00	+3.09%
10/28/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Sector Perform	$61.00 ➝ $72.00	+2.86%
10/28/2025	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Keay Nakae Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$72.00	+2.86%
10/28/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
10/27/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold
Get the Latest News and Ratings for RNA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.
10/27/2025	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boobalan Pachaiyappan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$72.00	+46.49%
10/27/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$65.00	+32.25%
10/27/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Martin Auster Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Market Perform
10/27/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Pickering Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$52.00 ➝ $72.00	+46.49%
10/27/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
9/15/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$56.00 ➝ $65.00	+60.42%
8/8/2025	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gena Wang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$59.00 ➝ $62.00	+30.47%
7/10/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Corinne Johnson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Buy	$55.00	+81.67%
6/27/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eric Schmidt Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$96.00	+221.82%
6/10/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gena Wang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$57.00 ➝ $59.00	+80.65%
3/12/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kostas Biliouris Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$72.00	+143.41%
3/7/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Louise Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Sector Outperform	$70.00	+130.64%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 07:39 PM ET.

RNA Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Avidity Biosciences is $69.42, with a high forecast of $96.00 and a low forecast of $55.00.

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last twelve months. There is currently 1 sell rating, 12 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RNA, but not buy additional shares or sell existing shares.

According to analysts, Avidity Biosciences's stock has a predicted upside of 431.15% based on their 12-month stock forecasts.

Over the previous 90 days, Avidity Biosciences's stock had 1 upgrade by analysts.

Avidity Biosciences has been rated by research analysts at HC Wainwright, and Wells Fargo & Company in the past 90 days.

Analysts like Avidity Biosciences more than other "medical" companies. The consensus rating score for Avidity Biosciences is 2.32 while the average consensus rating score for "medical" companies is 2.30. Learn more on how RNA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Avidity Biosciences Recommendations

This page (NASDAQ:RNA) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avidity Biosciences (RNA) Stock Forecast & Price Target

Avidity Biosciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

RNA Analyst Ratings Over Time

RNA Analyst Recommendations By Month

RNA Price Targets by Month

Avidity Biosciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

RNA Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Avidity Biosciences Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avidity Biosciences (RNA) Stock Forecast & Price Target

Avidity Biosciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

RNA Analyst Ratings Over Time

RNA Analyst Recommendations By Month

RNA Price Targets by Month

Avidity Biosciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

RNA Forecast - Frequently Asked Questions

What is Avidity Biosciences' forecast for 2026?

Should I buy or sell Avidity Biosciences stock right now?

Does Avidity Biosciences's stock price have much upside?

Has Avidity Biosciences been upgraded by Wall Street analysts recently?

What analysts cover Avidity Biosciences?

Do Wall Street analysts like Avidity Biosciences more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Avidity Biosciences Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools